STOCK COMMENTS / EPS CHANGESAmeren ( AEE) estimates, target reduced at UBS. AEE estimates were cut through 2013, UBS said. Company is seeing slower usage trends. Neutral rating and new $32 price target. Citigroup ( C) added to US 1 List at BofA/Merrill. C was placed on the US 1 list, Bank of America/Merrill Lynch said. The company trades at a discount to its peers, but its recovery is clearly on track. $45 price target. Celgene ( CELG) target raised at Jefferies to $94, Jefferies said. Abraxane shows survival benefit. Buy rating. Generac Holdings ( GNRC) numbers raised at BMO. Shares of GNRC now seen reaching $42, BMO said. Estimates also increased on recent storm caused demand. Outperform rating. Heartware ( HTWR) estimates, target cut at UBS. Shares of HTWR now seen reaching $100, according to UBS. Estimates also reduced, given slower international growth and expected adoption of HVAD. Buy rating. Medivation ( MDVN) numbers raised at Jefferies. Shares of MDVN now seen reaching $62, Jefferies said. Estimates also raised on Xtandi beat. Buy rating. Pfizer ( PFE) numbers lowered at Jefferies. Shares of PFE now seen reaching $27, Jefferies said. Estimates also lowered on revenue miss. Buy rating.
STRATEGY CALLS / MARKET CALLSTechnology and Media sectors downgraded at Wells from market-weight to underweight, Wells Fargo said. The Media sector was also cut from Overweight to Market-weight. Groups are leveraged to slower business spending. >To submit a news tip, email: email@example.com.
Twitter and become a fan on Facebook.